Source: http://texashhsc.swagit.com/play/01262018-612
Timestamp: 2020-06-02 21:38:25
Document Index: 694708558

Matched Legal Cases: ['art 1', 'art 2', 'art 15', 'art 15', 'art 1', 'art 2', 'art 1', 'art 2', 'art 15']

January 26, 2018 Drug Utilization Review Board - Texas Health and Human Services Commission
January 26, 2018 Drug Utilization Review Board
Item 2 - Approval of minutes from November 3, 2017 (Vote required)
Item 3 - Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the November 3, 2017, meeting
Old business: Report on Health and Human Services Commission decisions on acceptance of
the Drug Utilization Review (DUR) Board recommendations from the November 3, 2017,
Item 4 (Part 1 of 2) - New business: Public comment on drug classes to be reviewed and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL): a. Acne agents, oral (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4a-acne-agents-oralcurrent_ product-listing.pdf) b. Acne agents, topical (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4b-acne-agents-topical.pdf) c. Analgesics, narcotic long (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4c-analgesics-narcotic-longacting. pdf) d. Analgesics, narcotic short (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4d-analgesics-narcotic-shortacting. pdf) e. Angiotensin modulator combinations (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4e-angiotensin-modulators-combinations.pdf) f. Angiotensin modulators (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4f-angiotensin-modulators.pdf) g. Antimigraine agents, other (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4g-antimigraine-agents-othercurrent- product-listing.pdf) h. Antimigraine agents, triptans (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4h-antimigraine-agentstriptans. pdf) i. Bladder relaxant preparations (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4i-bladder-relaxants-preparations.pdf) j. H. pylori treatment (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4j-hpylori-treatments.pdf) k. Immunomodulators, atopic dermatitis (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/012618/4k-immunomodulators-atopic-dermatitis.pdf) l. Intranasal rhinitis agents (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4l-intranasal-rhinitis.pdf) m. Movement disorders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4m-movement-disorders.pdf) n. Neuropathic pain (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4n-neuropathic-pain.pdf) o. Ophthalmics, anti-inflammatory/immunomodulator (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4o-ophthalmics-antiInflammatoryimmunomodulator. pdf) p. Phosphate binders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4p-phosphate-binders.pdf) q. Platelet aggregation inhibitors (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4q-platelet-aggregation-inhibitors.pdf) r. Progestins for cachexia (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4r-progestins-for-cachexiaretired. pdf) s. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4s-proton-pump-inhibitors.pdf) t. Smoking cessation (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4t-smoking-cessationagents. pdf)
Public comment on drug classes to be reviewed and clinical drug reviews to be reviewed for the
Medicaid Preferred Drug List (PDL):
a. Acne agents, oral (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4a-acne-agents-oralcurrent_
product-listing.pdf)
b. Acne agents, topical (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4b-acne-agents-topical.pdf)
c. Analgesics, narcotic long (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4c-analgesics-narcotic-longacting.
d. Analgesics, narcotic short (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4d-analgesics-narcotic-shortacting.
meetings-events/dur/012618/4e-angiotensin-modulators-combinations.pdf)
f. Angiotensin modulators (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4f-angiotensin-modulators.pdf)
g. Antimigraine agents, other (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4g-antimigraine-agents-othercurrent-
h. Antimigraine agents, triptans (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4h-antimigraine-agentstriptans.
meetings-events/dur/012618/4i-bladder-relaxants-preparations.pdf)
j. H. pylori treatment (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4j-hpylori-treatments.pdf)
(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/012618/4k-immunomodulators-atopic-dermatitis.pdf)
l. Intranasal rhinitis agents (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4l-intranasal-rhinitis.pdf)
m. Movement disorders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4m-movement-disorders.pdf)
n. Neuropathic pain (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4n-neuropathic-pain.pdf)
o. Ophthalmics, anti-inflammatory/immunomodulator
meetings-events/dur/012618/4o-ophthalmics-antiInflammatoryimmunomodulator.
p. Phosphate binders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4p-phosphate-binders.pdf)
meetings-events/dur/012618/4q-platelet-aggregation-inhibitors.pdf)
r. Progestins for cachexia (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4r-progestins-for-cachexiaretired.
s. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4s-proton-pump-inhibitors.pdf)
t. Smoking cessation (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4t-smoking-cessationagents.
Item 4 (Part 2 of 2) - Public comment on new drugs to be reviewed for the Medicaid PDL: 1. Gastrointestinal (GI) motility, chronic / Symproic (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-1-gastointestinal-motility-chronic-symproicndu. pdf) 2. Glucocorticoids, inhaled / Armonair Respiclick (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-2-glucocorticoids-inhaled-armonair-respiclick.pdf) 3. Glucocorticoids, inhaled / Trelegy Ellipta (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-3-glucocorticoids-inhaled-trelegy-ellipta-ndu.pdf) 4. Glucocorticoids, oral / Zodex (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4-4-glucocorticoids-oralzodex. pdf) 5. HAE treatments / Haegarda (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/4-5-hae-treatmentshaegarda. pdf) 6. Hypoglycemics, insulin and related agents / Fiasp FlexTouch pen (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-6-hypoglycemics-insulins-fiasp-flextouch-pen.pdf) 7. Hypoglycemics, insulin and related agents / Fiasp vial (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-7-hypoglycemics-insulins-fiasp-vial.pdf) 8. Hypoglycemics, insulin and related agents / Humalog Junior KwikPen (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-8-hypoglycemics-insulins-humalog-juniorkwikpen. pdf) 9. Stimulants and related agents / Cotempla XR-ODT (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/4-9-stimulants-related-agents-cotempla-xr-odt.pdf)
1. Gastrointestinal (GI) motility, chronic / Symproic
meetings-events/dur/012618/4-1-gastointestinal-motility-chronic-symproicndu.
2. Glucocorticoids, inhaled / Armonair Respiclick
meetings-events/dur/012618/4-2-glucocorticoids-inhaled-armonair-respiclick.pdf)
3. Glucocorticoids, inhaled / Trelegy Ellipta
meetings-events/dur/012618/4-3-glucocorticoids-inhaled-trelegy-ellipta-ndu.pdf)
4. Glucocorticoids, oral / Zodex (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4-4-glucocorticoids-oralzodex.
5. HAE treatments / Haegarda (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/4-5-hae-treatmentshaegarda.
6. Hypoglycemics, insulin and related agents / Fiasp FlexTouch pen
meetings-events/dur/012618/4-6-hypoglycemics-insulins-fiasp-flextouch-pen.pdf)
7. Hypoglycemics, insulin and related agents / Fiasp vial
meetings-events/dur/012618/4-7-hypoglycemics-insulins-fiasp-vial.pdf)
8. Hypoglycemics, insulin and related agents / Humalog Junior KwikPen
meetings-events/dur/012618/4-8-hypoglycemics-insulins-humalog-juniorkwikpen.
9. Stimulants and related agents / Cotempla XR-ODT
meetings-events/dur/012618/4-9-stimulants-related-agents-cotempla-xr-odt.pdf)
Item 5 - Executive work session Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas
Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may
meet in executive session on one or more items listed under new business as permitted by the
Texas Open Meetings Act.
Item 7 - Announcements of drugs recommended for the Medicaid PDL
Item 8 - Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC a. Report on recent retrospective DUR intervention sent for high dose attention deficit hyperactivity disorder medication management in youth b. Report on recent retrospective DUR intervention outcomes for GI management c. Retrospective DUR proposals: (Vote required) i. Hypertension management (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/8c-i-hypertension-management.pdf) ii. Major depressive disorder management (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/8c-ii-major-depressive-disordermanagement. pdf) iii. Benzodiazepine anxiolytics and controlled sedative hypnotics (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/8c-iii-benzodiazepine-anxiolytics-controlledsedative- hypnotics.pdf)
a. Report on recent retrospective DUR intervention sent for high dose attention deficit
hyperactivity disorder medication management in youth
b. Report on recent retrospective DUR intervention outcomes for GI management
meetings-events/dur/012618/8c-i-hypertension-management.pdf)
meetings-events/dur/012618/8c-ii-major-depressive-disordermanagement.
iii. Benzodiazepine anxiolytics and controlled sedative hypnotics
meetings-events/dur/012618/8c-iii-benzodiazepine-anxiolytics-controlledsedative-
hypnotics.pdf)
Item 9 - Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (Vote required) a. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/9a-proton-pumpinhibitors. pdf) b. Topical retinoids (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/9b-topical-retinoids.pdf)
Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health
Information Designs, LLC (Vote required)
a. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/9a-proton-pumpinhibitors.
b. Topical retinoids (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/9b-topical-retinoids.pdf)
Items 10 - 12 - 10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (Vote required) a. Fentanyl (inhalation/oral/transdermal) (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/10a-fentanyl.pdf) b. Gabapentin (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/10b-gabapentin.pdf) c. Hydrocodone Bitartrate/Hydrocodone Polistirex (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/10c-hydrocodone-bitartrate-hydrocondepolistirex. pdf) d. Ivacaftor (Kalydeco®) and Lumacaftor/Ivacaftor (Orkambi®) (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/10d-ivacaftor-lumacaftor-ivacaftor.pdf) e. Calcineurin Inhibitors - Pimecrolimus (Elidel®), Tacrolimus (Protopic®) (https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/ meetings-events/dur/012618/10e-calcineurin-inhibitors-primecrolimustacrolimus. pdf) f. Tramadol (Ultram®) (https://hhs.texas.gov/sites/default/files//documents/abouthhs/ communications-events/meetings-events/dur/012618/10f-tramadol.pdf) 11. Adjourn 12. Next meeting date: April 27, 2018
10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer,
Pharm. D., University of Texas at Austin College of Pharmacy (Vote required)
a. Fentanyl (inhalation/oral/transdermal)
meetings-events/dur/012618/10a-fentanyl.pdf)
b. Gabapentin (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/10b-gabapentin.pdf)
c. Hydrocodone Bitartrate/Hydrocodone Polistirex
meetings-events/dur/012618/10c-hydrocodone-bitartrate-hydrocondepolistirex.
d. Ivacaftor (Kalydeco®) and Lumacaftor/Ivacaftor (Orkambi®)
meetings-events/dur/012618/10d-ivacaftor-lumacaftor-ivacaftor.pdf)
e. Calcineurin Inhibitors - Pimecrolimus (Elidel®), Tacrolimus (Protopic®)
meetings-events/dur/012618/10e-calcineurin-inhibitors-primecrolimustacrolimus.
f. Tramadol (Ultram®) (https://hhs.texas.gov/sites/default/files//documents/abouthhs/
communications-events/meetings-events/dur/012618/10f-tramadol.pdf)
12. Next meeting date: April 27, 2018
Item 1 - Call to order Item 2 - Approval of minutes from November 3, 2017 (Vote re... Item 3 - Old business: Report on Health and Human Services ... Item 4 (Part 1 of 2) - New business: Public comment on dru... Item 4 (Part 2 of 2) - Public comment on new drugs to be re... Item 5 - Executive work session Pursuant to Texas Governmen... Item 7 - Announcements of drugs recommended for the Medicai... Item 8 - Retrospective DUR: Larry Dent, Pharm. D., BCPS, Co... Item 9 - Prospective prior authorization proposals (clinica... Items 10 - 12 - 10. Retrospective drug use, criteria for ou...
'); // 480x380 to 640x360 jQuery("#segment_embed").val(' '); addthis.toolbox("#toolbox", {"data_track_addressbar":false, "data_track_clickback":false}, {"url":"https://texashhsc.swagit.com/play/01262018-612/" + the_item.mediaid}); // val = the_item.id; val = the_item.mediaid; jQuery("div[id=segment-" + val + "]").children('.extra').toggle(true); jQuery("div[id=segment-" + val + "]").children('.collapsed').children('.segment-title').css("font-weight", "normal") jQuery("div[id=segment-" + val + "]").children('.collapsed').css('hover', '#d7ddeb'); jQuery("div[id=segment-" + val + "]").children('.collapsed').css('background', '#edf0f6'); jQuery(".segment").css('border', 'none'); jQuery(".segment").css('border-bottom', '1px solid #cccccc'); jQuery("div[id=segment-" + val + "]").css('border', '2px solid #d7ddeb'); // seems to work in jwp // document.getElementById('tabs-1').scrollTop = document.getElementById(val).offsetTop - document.getElementById('tabs-1').offsetTop; }); var show_cc1 = false; var first_cc_load = true; /* player.on('play', function() { console.log('onplay'); if (seekFlag) { console.log('seeking'); seekFlag = false; player.currentTime(seekTo); } }); */ player.on('loadedmetadata', function() { console.log('onloadedmetadata'); if (seekFlag) { console.log('seeking'); seekFlag = false; player.currentTime(seekTo); } }); /* player.on('playing', function() { console.log('onplaying'); if (seekFlag) { console.log('seeking'); seekFlag = false; setTimeout(function(){ player.currentTime(seekTo); }, 1000) } }); */ /* // Add the event handler player.on('timeupdate', timeupdateHandler); //Handle the event then remove JUST this event listener on timeupdate function timeupdateHandler(evt) { if (seekFlag) { console.log('ontimeupdate & seek'); console.log('seeking'); seekFlag = false; } } */	player.on('playlistitem', function() { console.log('pli, setting first_cc_load'); first_cc_load = true; }); player.textTracks().on('change', function(one,two) { var tracks = player.textTracks(); for (var i = 0; i < tracks.length; i++) { var track = tracks[i]; if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'showing') { show_cc1 = true; } else if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'disabled') { show_cc1 = false; } } }); player.on('texttrackchange', function(one,two) { var tracks = player.textTracks(); console.log("ttc: " + first_cc_load); for (var i = 0; i < tracks.length; i++) { var track = tracks[i]; if (track.kind === 'captions' && track.label === 'cc1' && track.mode === 'disabled' && show_cc1 && first_cc_load) { this.ready(function(){ setTimeout(function(){ track.mode = 'showing'; }, 0); }); } } first_cc_load = false; }); // playlist-change-block player.on('playlistchange', function() { console.log('plc'); if (location.hash) { hash = location.hash.replace(/^#/, '') hash = hash.replace(/^&start=/, '') jQuery.each(playlist, function(item, value) { if (value['mediaid'] == hash) { player.playlist.currentItem(item); } }); } jQuery(window).hashchange( function(){ hash = location.hash.replace(/^#/, '') hash = hash.replace(/^&start=/, '') if (hash.match(/^i/)) { hash = hash.replace(/^i/, '') jQuery.each(playlist, function(item, value) { if (value['imported_mediaid'] == hash) { player.playlist.currentItem(item); } }); } else if (hash.match(/^t/)) { hash = hash.replace(/^t/, '') jwplayer("player").seek(hash); } else { jQuery.each(playlist, function(item, value) { if (value['mediaid'] == hash) { player.playlist.currentItem(item); } }); } }); // /playlist-change-block }); var playlist = [{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-613.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-613.480x360.jpg?r=2","mediaid":2,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-613.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-613.480x360.jpg?r=2","description":"Call to order","title":"Item 1 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-613.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-614.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-614.480x360.jpg?r=2","mediaid":3,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-614.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-614.480x360.jpg?r=2","description":"Approval of minutes from November 3, 2017 (Vote required)","title":"Item 2 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-614.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-615.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-615.480x360.jpg?r=2","mediaid":4,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-615.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-615.480x360.jpg?r=2","description":"Old business: Report on Health and Human Services Commission decisions on acceptance of\nthe Drug Utilization Review (DUR) Board recommendations from the November 3, 2017,\nmeeting","title":"Item 3 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-615.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-616.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-616.480x360.jpg?r=2","mediaid":5,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-616.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-616.480x360.jpg?r=2","description":"New business:\n\nPublic comment on drug classes to be reviewed and clinical drug reviews to be reviewed for the\nMedicaid Preferred Drug List (PDL):\n\na. Acne agents, oral (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4a-acne-agents-oralcurrent_\nproduct-listing.pdf)\nb. Acne agents, topical (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4b-acne-agents-topical.pdf)\nc. Analgesics, narcotic long (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4c-analgesics-narcotic-longacting.\npdf)\nd. Analgesics, narcotic short (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4d-analgesics-narcotic-shortacting.\npdf)\ne. Angiotensin modulator combinations\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4e-angiotensin-modulators-combinations.pdf)\nf. Angiotensin modulators (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4f-angiotensin-modulators.pdf)\ng. Antimigraine agents, other (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4g-antimigraine-agents-othercurrent-\nproduct-listing.pdf)\nh. Antimigraine agents, triptans (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4h-antimigraine-agentstriptans.\npdf)\ni. Bladder relaxant preparations\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4i-bladder-relaxants-preparations.pdf)\nj. H. pylori treatment (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4j-hpylori-treatments.pdf)\nk. Immunomodulators, atopic dermatitis\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communications-events/meetings-events/dur/012618/4k-immunomodulators-atopic-dermatitis.pdf)\nl. Intranasal rhinitis agents (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4l-intranasal-rhinitis.pdf)\nm. Movement disorders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4m-movement-disorders.pdf)\nn. Neuropathic pain (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4n-neuropathic-pain.pdf)\no. Ophthalmics, anti-inflammatory/immunomodulator\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4o-ophthalmics-antiInflammatoryimmunomodulator.\npdf)\np. Phosphate binders (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4p-phosphate-binders.pdf)\nq. Platelet aggregation inhibitors\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4q-platelet-aggregation-inhibitors.pdf)\nr. Progestins for cachexia (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4r-progestins-for-cachexiaretired.\npdf)\ns. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4s-proton-pump-inhibitors.pdf)\nt. Smoking cessation (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4t-smoking-cessationagents.\npdf)","title":"Item 4 (Part 1 of 2) ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-616.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-617.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-617.480x360.jpg?r=2","mediaid":6,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-617.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-617.480x360.jpg?r=2","description":"Public comment on new drugs to be reviewed for the Medicaid PDL:\n1. Gastrointestinal (GI) motility, chronic / Symproic\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-1-gastointestinal-motility-chronic-symproicndu.\npdf)\n2. Glucocorticoids, inhaled / Armonair Respiclick\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-2-glucocorticoids-inhaled-armonair-respiclick.pdf)\n3. Glucocorticoids, inhaled / Trelegy Ellipta\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-3-glucocorticoids-inhaled-trelegy-ellipta-ndu.pdf)\n4. Glucocorticoids, oral / Zodex (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4-4-glucocorticoids-oralzodex.\npdf)\n5. HAE treatments / Haegarda (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/4-5-hae-treatmentshaegarda.\npdf)\n6. Hypoglycemics, insulin and related agents / Fiasp FlexTouch pen\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-6-hypoglycemics-insulins-fiasp-flextouch-pen.pdf)\n7. Hypoglycemics, insulin and related agents / Fiasp vial\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-7-hypoglycemics-insulins-fiasp-vial.pdf)\n8. Hypoglycemics, insulin and related agents / Humalog Junior KwikPen\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-8-hypoglycemics-insulins-humalog-juniorkwikpen.\npdf)\n9. Stimulants and related agents / Cotempla XR-ODT\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/4-9-stimulants-related-agents-cotempla-xr-odt.pdf)","title":"Item 4 (Part 2 of 2) ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-617.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-618.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-618.480x360.jpg?r=2","mediaid":7,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-618.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-618.480x360.jpg?r=2","description":"Executive work session\nPursuant to Texas Government Code, Section 531.071, and in accordance with Texas\nAdministrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may\nmeet in executive session on one or more items listed under new business as permitted by the\nTexas Open Meetings Act.","title":"Item 5 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-618.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-619.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-619.480x360.jpg?r=2","mediaid":8,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-619.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-619.480x360.jpg?r=2","description":"Announcements of drugs recommended for the Medicaid PDL","title":"Item 7 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-619.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-620.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-620.480x360.jpg?r=2","mediaid":9,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-620.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-620.480x360.jpg?r=2","description":"Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC\n\na. Report on recent retrospective DUR intervention sent for high dose attention deficit\nhyperactivity disorder medication management in youth\nb. Report on recent retrospective DUR intervention outcomes for GI management\nc. Retrospective DUR proposals: (Vote required)\ni. Hypertension management\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/8c-i-hypertension-management.pdf)\nii. Major depressive disorder management\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/8c-ii-major-depressive-disordermanagement.\npdf)\niii. Benzodiazepine anxiolytics and controlled sedative hypnotics\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/8c-iii-benzodiazepine-anxiolytics-controlledsedative-\nhypnotics.pdf)","title":"Item 8 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-620.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-621.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-621.480x360.jpg?r=2","mediaid":10,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-621.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-621.480x360.jpg?r=2","description":"Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health\nInformation Designs, LLC (Vote required)\n\na. Proton pump inhibitors (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/9a-proton-pumpinhibitors.\npdf)\nb. Topical retinoids (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/9b-topical-retinoids.pdf)","title":"Item 9 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-621.480x360.jpg?r=2"},{"sources":[{"src":"https://stream.us-central1-b.swagit.com/on-demand/_definst_/media1/2018/01/26/01262018-622.360.mp4/playlist.m3u8","type":"application/x-mpegURL"}],"poster":"https://stills.swagit.com/stills/2018/01/26/01262018-622.480x360.jpg?r=2","mediaid":11,"dfile":"https://media.swagit.com/podcasts/2018/01/26/01262018-622.360.mp4","smimage":"https://stills.swagit.com/stills/2018/01/26/01262018-622.480x360.jpg?r=2","description":"10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer,\nPharm. D., University of Texas at Austin College of Pharmacy (Vote required)\na. Fentanyl (inhalation/oral/transdermal)\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/10a-fentanyl.pdf)\nb. Gabapentin (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/10b-gabapentin.pdf)\nc. Hydrocodone Bitartrate/Hydrocodone Polistirex\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/10c-hydrocodone-bitartrate-hydrocondepolistirex.\npdf)\nd. Ivacaftor (Kalydeco\u00ae) and Lumacaftor/Ivacaftor (Orkambi\u00ae)\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/10d-ivacaftor-lumacaftor-ivacaftor.pdf)\ne. Calcineurin Inhibitors - Pimecrolimus (Elidel\u00ae), Tacrolimus (Protopic\u00ae)\n(https://hhs.texas.gov/sites/default/files//documents/about-hhs/communicationsevents/\nmeetings-events/dur/012618/10e-calcineurin-inhibitors-primecrolimustacrolimus.\npdf)\nf. Tramadol (Ultram\u00ae) (https://hhs.texas.gov/sites/default/files//documents/abouthhs/\ncommunications-events/meetings-events/dur/012618/10f-tramadol.pdf)\n\n11. Adjourn\n\n12. Next meeting date: April 27, 2018","title":"Items 10 - 12 ","image":"https://stills.swagit.com/stills/2018/01/26/01262018-622.480x360.jpg?r=2"}]; player.playlist([]); player.playlist(playlist); // Play through the playlist automatically. player.playlist.autoadvance(0);